237 related articles for article (PubMed ID: 33243988)
1. A stem cell reporter based platform to identify and target drug resistant stem cells in myeloid leukemia.
Spinler K; Bajaj J; Ito T; Zimdahl B; Hamilton M; Ahmadi A; Koechlein CS; Lytle N; Kwon HY; Anower-E-Khuda F; Sun H; Blevins A; Weeks J; Kritzik M; Karlseder J; Ginsberg MH; Park PW; Esko JD; Reya T
Nat Commun; 2020 Nov; 11(1):5998. PubMed ID: 33243988
[TBL] [Abstract][Full Text] [Related]
2. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
3. In vitro sensitivity of hematopoietic progenitors to tiazofurin in refractory acute myeloid leukemia and in the blast crisis of chronic myeloid leukemia.
Colovic M; Sefer D; Bogdanovic A; Suvajdzic N; Jankovic G; Atkinson HD; Milenkovic P
Cancer Lett; 2003 Jun; 195(2):153-9. PubMed ID: 12767523
[TBL] [Abstract][Full Text] [Related]
4. Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
Garg S; Shanmukhaiah C; Ghosh K; Madkaikar M
Leuk Lymphoma; 2016 Sep; 57(9):2195-8. PubMed ID: 26700494
[No Abstract] [Full Text] [Related]
5. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
6. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
7. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
Guzman ML; Rossi RM; Karnischky L; Li X; Peterson DR; Howard DS; Jordan CT
Blood; 2005 Jun; 105(11):4163-9. PubMed ID: 15687234
[TBL] [Abstract][Full Text] [Related]
8. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Dasgupta Y; Koptyra M; Hoser G; Kantekure K; Roy D; Gornicka B; Nieborowska-Skorska M; Bolton-Gillespie E; Cerny-Reiterer S; Müschen M; Valent P; Wasik MA; Richardson C; Hantschel O; van der Kuip H; Stoklosa T; Skorski T
Blood; 2016 Apr; 127(17):2131-43. PubMed ID: 26864341
[TBL] [Abstract][Full Text] [Related]
9. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
10. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia.
Kharas MG; Lengner CJ; Al-Shahrour F; Bullinger L; Ball B; Zaidi S; Morgan K; Tam W; Paktinat M; Okabe R; Gozo M; Einhorn W; Lane SW; Scholl C; Fröhling S; Fleming M; Ebert BL; Gilliland DG; Jaenisch R; Daley GQ
Nat Med; 2010 Aug; 16(8):903-8. PubMed ID: 20616797
[TBL] [Abstract][Full Text] [Related]
11. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.
Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
[TBL] [Abstract][Full Text] [Related]
12. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
[TBL] [Abstract][Full Text] [Related]
13. An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia.
Bajaj J; Hamilton M; Shima Y; Chambers K; Spinler K; Van Nostrand EL; Yee BA; Blue SM; Chen M; Rizzeri D; Chuah C; Oehler VG; Broome HE; Sasik R; Scott-Browne J; Rao A; Yeo GW; Reya T
Nat Cancer; 2020 Apr; 1(4):410-422. PubMed ID: 34109316
[TBL] [Abstract][Full Text] [Related]
14. Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia.
Kwon HY; Bajaj J; Ito T; Blevins A; Konuma T; Weeks J; Lytle NK; Koechlein CS; Rizzieri D; Chuah C; Oehler VG; Sasik R; Hardiman G; Reya T
Cell Stem Cell; 2015 Aug; 17(2):152-164. PubMed ID: 26212080
[TBL] [Abstract][Full Text] [Related]
15. Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia.
Brennan L; Narendran A
Stem Cells Dev; 2019 Oct; 28(19):1277-1287. PubMed ID: 31364487
[TBL] [Abstract][Full Text] [Related]
16.
Magistroni V; Mauri M; D'Aliberti D; Mezzatesta C; Crespiatico I; Nava M; Fontana D; Sharma N; Parker W; Schreiber A; Yeung D; Pirola A; Readelli S; Massimino L; Wang P; Khandelwal P; Citterio S; Viltadi M; Bombelli S; Rigolio R; Perego R; Boultwood J; Morotti A; Saglio G; Kim DW; Branford S; Gambacorti-Passerini C; Piazza R
Haematologica; 2019 Sep; 104(9):1789-1797. PubMed ID: 30819912
[TBL] [Abstract][Full Text] [Related]
17. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
18. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.
Stoklosa T; Glodkowska-Mrowka E; Hoser G; Kielak M; Seferynska I; Wlodarski P
Exp Hematol; 2013 May; 41(5):462-9. PubMed ID: 23395818
[TBL] [Abstract][Full Text] [Related]
19. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8).
Guzman ML; Li X; Corbett CA; Rossi RM; Bushnell T; Liesveld JL; Hébert J; Young F; Jordan CT
Blood; 2007 Dec; 110(13):4436-44. PubMed ID: 17785584
[TBL] [Abstract][Full Text] [Related]
20. Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.
Shlush LI; Chapal-Ilani N; Adar R; Pery N; Maruvka Y; Spiro A; Shouval R; Rowe JM; Tzukerman M; Bercovich D; Izraeli S; Marcucci G; Bloomfield CD; Zuckerman T; Skorecki K; Shapiro E
Blood; 2012 Jul; 120(3):603-12. PubMed ID: 22645183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
